Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy
Zitieren Sie bitte immer diese URN: urn:nbn:de:bvb:20-opus-125705
- Virotherapy on the basis of oncolytic vaccinia virus (VACV) strains is a novel approach for canine cancer therapy. Here we describe, for the first time, the characterization and the use of VACV strain GLV-5b451 expressing the anti-vascular endothelial growth factor (VEGF) single-chain antibody (scAb) GLAF-2 as therapeutic agent against different canine cancers. Cell culture data demonstrated that GLV-5b451 efficiently infected and destroyed all four tested canine cancer cell lines including: mammary carcinoma (MTH52c), mammary adenoma (ZMTH3),Virotherapy on the basis of oncolytic vaccinia virus (VACV) strains is a novel approach for canine cancer therapy. Here we describe, for the first time, the characterization and the use of VACV strain GLV-5b451 expressing the anti-vascular endothelial growth factor (VEGF) single-chain antibody (scAb) GLAF-2 as therapeutic agent against different canine cancers. Cell culture data demonstrated that GLV-5b451 efficiently infected and destroyed all four tested canine cancer cell lines including: mammary carcinoma (MTH52c), mammary adenoma (ZMTH3), prostate carcinoma (CT1258), and soft tissue sarcoma (STSA-1). The GLV-5b451 virus-mediated production of GLAF-2 antibody was observed in all four cancer cell lines. In addition, this antibody specifically recognized canine VEGF. Finally, in canine soft tissue sarcoma (CSTS) xenografted mice, a single systemic administration of GLV-5b451 was found to be safe and led to anti-tumor effects resulting in the significant reduction and substantial long-term inhibition of tumor growth. A CD31-based immuno-staining showed significantly decreased neo-angiogenesis in GLV-5b451-treated tumors compared to the controls. In summary, these findings indicate that GLV-5b451 has potential for use as a therapeutic agent in the treatment of CSTS.…
Autor(en): | Marion Adelfinger, Simon Bessler, Alexander Cecil, Johanna Langbein-Laugwitz, Alexa Frentzen, Ivaylo Gentschev, Aladar A. Szalay |
---|---|
URN: | urn:nbn:de:bvb:20-opus-125705 |
Dokumentart: | Artikel / Aufsatz in einer Zeitschrift |
Institute der Universität: | Fakultät für Biologie / Julius-von-Sachs-Institut für Biowissenschaften |
Fakultät für Chemie und Pharmazie / Lehrstuhl für Biochemie | |
Sprache der Veröffentlichung: | Englisch |
Titel des übergeordneten Werkes / der Zeitschrift (Englisch): | Viruses |
Erscheinungsjahr: | 2015 |
Band / Jahrgang: | 7 |
Seitenangabe: | 4075-4092 |
Originalveröffentlichung / Quelle: | Viruses 2015, 7, 4075-4092; doi:10.3390/v7072811 |
DOI: | https://doi.org/10.3390/v7072811 |
Allgemeine fachliche Zuordnung (DDC-Klassifikation): | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Freie Schlagwort(e): | angiogenesis; antibody production; cancer; canine cancer cell lines; canine cancer therapy; canine soft tissue sarcoma (CSTS); oncolytic virus |
Datum der Freischaltung: | 02.02.2016 |
Sammlungen: | Open-Access-Publikationsfonds / Förderzeitraum 2015 |
Lizenz (Deutsch): | CC BY: Creative-Commons-Lizenz: Namensnennung |